Jiangsu Hansoh Pharmaceutical, Shanghai Hansoh Biomedical identify agents targeting 5-HT2A/DRD3 Aug. 17, 2020
New selective NKCC1 inhibitor for neurological conditions with impaired chloride ion homeostasis Aug. 17, 2020
Healx enters a new partnership to accelerate development of therapeutics for Angelman Syndrome Aug. 14, 2020
FDA approves Viltepso for the treatment of DMD in patients amenable to exon 53 skipping therapy Aug. 13, 2020
RSS